New Chief Financial Officer Assumes Role at Pulse Biosciences

Pulse Biosciences Inc., a bioelectric medicine company bringing to market its proprietary CellFX System, announced that Sandra (Sandy) Gardiner joined the company as executive vice president and chief financial officer (CFO). Gardiner comes to Pulse Biosciences with 30 years of financial, operational and strategic leadership experience in the life sciences, including 20 years in medical devices. Brian Dow resigned as senior vice president and CFO to pursue other interests, but he will continue with the company in a transitional role until Dec. 31.
 
“The Board of Directors and I are sincerely grateful to Brian for his contributions in helping to build Pulse Biosciences from a small private technology company to a public clinical stage company planning for commercialization of our proprietary and novel CellFX System. Brian has played an instrumental role during this early stage of the company, helping to execute our successful IPO in 2016 and as a key team member as we have continued to build the company. I’m grateful that Brian will assist with a smooth transition and we wish him well in his next endeavor,” said Darrin Uecker, president and CEO of Pulse Biosciences. “Sandy brings a wealth of experience to Pulse Biosciences that is ideal at this exciting point in our ongoing growth. She is a seasoned executive with a proven track record in medical devices, including in the global aesthetic device market, and I look forward to her joining our team as we drive our transition to a global commercial company.”
 
“I’ve thoroughly enjoyed my time as part of the Pulse Biosciences team and am proud of the many contributions we made to launch and build the company,” said Dow. 
 
Gardiner was most recently executive vice president and CFO of Cutera Inc., a global provider of laser, light, and other energy-based aesthetic systems. Prior to that, Gardiner served as vice president and CFO of Tria Beauty Inc., a medical device manufacturer of laser based aesthetic devices. Prior to these roles, Gardiner held a series of vice president and CFO positions with both publicly traded and privately held companies. Gardiner earned her bachelor of arts degree in management economics from the University of California, Davis.

“Joining the Pulse Biosciences team as it prepares for commercialization of its proprietary and novel CellFX System and its potential to deliver a broad array of high value applications to the aesthetic dermatology procedure market is a unique and exciting opportunity for me,” said Gardiner. “I look forward to working with the Pulse Biosciences team as it transitions to a viable global commercial company in the aesthetic procedure market.”
 
Pulse Biosciences is a bioelectric medicine company committed to health innovation that improves and potentially extends the lives of patients. The CellFX System is the first planned commercial product to harness the distinctive advantages of the company’s proprietary Nano-Pulse Stimulation (NPS) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of ongoing clinical trials. The CellFX System is preparing to launch in 2019 as a multi-application platform designed to address a broad range of dermatologic conditions. As part of the customer experience, the company is offering a utilization-based revenue model and easy-access customer portal offering a suite of services. CellFX procedures offer customer value across an expanding spectrum of clinical applications. The initial commercial use will be in the clearance of common and difficult-to-treat skin lesions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that lead to greater overall satisfaction.

Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation (NPS) technology are for investigational use only.